Abstract
Canavan disease (CD) is a rare fatal childhood neurological autosomal recessive genetic disease caused by mutations in the ASPA gene, which lead to catalytic deficiency of the ASPA enzyme, which catalyzes the hydrolysis of N-acetyl-L-aspartate (NAA) into aspartate and acetate. CD occurs frequently among Ashkenazi Jewish population, however it has been reported in many other ethnic groups with significantly lower frequency. Here, we report on two Egyptian patients diagnosed with CD, the first patient harbors five missense mutations (c.427 A > G; p. I143V, c.502C > T; p. R168C, c.530 T > C; p. I177T, c.557 T > C; p. V186D c.548C > T; p. P183L) and a silent mutation (c.693 C > T; p. Y231Y). The second patient was found to be homozygous for two missense mutations (c.427 A > G; p. I143V and c.557 T > A; p. V186D). Furthermore, molecular modeling of the novel mutation p. P183L provides an instructive explanation of the mutational impact on the protein structure that can affect the function of the ASPA. Here, the clinical, radiological, and biochemical profile of the two patients are reviewed in details.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bitto E, Bingman CA, Wesenberg GE, McCoy JG, GN JP (2007) Structure of aspartoacylase, the brain enzyme impaired in Canavan disease. Proc Natl Acad Sci U S A 104(2):456–461. doi:10.1073/pnas.0607817104
Di Pietro V, Cavallari U, Amorini AM, Lazzarino G, Longo S, Poggiani C, Cavalli P, Tavazzi B (2013) New T530C mutation in the aspartoacylase gene caused Canavan disease with no correlation between severity and N-acetylaspartate excretion. Clin Biochem 46(18):1902–1904. doi:10.1016/j.clinbiochem.2013.09.004
Elpeleg ON, Shaag A (1999) The spectrum of mutations of the aspartoacylase gene in Canavan disease in non-Jewish patients. J Inherit Metab Dis 22(4):531–534
Gajendrarao P, Krishnamoorthy N, Kassem H, Moharem-Elgamal S, Cecchi F, Olivotto I, Yacoub MH (2013) Molecular modeling of disease causing mutations in domain C1 of cMyBP-C. PLoS One 8(3):e59206. doi:10.1371/journal.pone.0059206
Gujar SK, Maheshwari S, Bjorkman-Burtscher I, Sundgren PC (2005) Magnetic resonance spectroscopy. J Neuroophthalmol 25(3):217–226
Hafez M, El-Tahan H, Awadalla M, El-Khayat H, Abdel-Gafar A, Ghoneim M (1983) Consanguineous matings in the Egyptian population. J Med Genet 20(1):58–60
Hershfield JR, Pattabiraman N, Madhavarao CN, Namboodiri MA (2007) Mutational analysis of aspartoacylase: implications for Canavan disease. Brain Res 1148:1–14. doi:10.1016/j.brainres.2007.02.069
Hoshino H, Kubota M (2014) Canavan disease: clinical features and recent advances in research. Pediatr Int 56(4):477–483. doi:10.1111/ped.12422
Kaul R, Gao GP, Matalon R, Aloya M, Su Q, Jin M, Johnson AB, Schutgens RB, Clarke JT (1996) Identification and expression of eight novel mutations among non-Jewish patients with Canavan disease. Am J Hum Genet 59(1):95–102
Krishnamoorthy N, Zayed H (2016) Structural modeling of p.V31F variant in the aspartoacylase gene. Metab Brain Dis. doi:10.1007/s11011–016-9796-z
Kumar S, Mattan NS, de Vellis J (2006) Canavan disease: a white matter disorder. Ment Retard Dev Disabil Res Rev 12(2):157–165. doi:10.1002/mrdd.20108
Le Coq J, Pavlovsky A, Malik R, Sanishvili R, Xu C, Viola RE (2008) Examination of the mechanism of human brain aspartoacylase through the binding of an intermediate analogue. Biochemistry 47(11):3484–3492. doi:10.1021/bi702400x
Madhavarao CN, Moffett JR, Moore RA, Viola RE, Namboodiri MA, Jacobowitz DM (2004) Immunohistochemical localization of aspartoacylase in the rat central nervous system. J Comp Neurol 472(3):318–329. doi:10.1002/cne.20080
Makarova KS, Grishin NV (1999) The Zn-peptidase superfamily: functional convergence after evolutionary divergence. J Mol Biol 292(1):11–17. doi:10.1006/jmbi.1999.3059
Michel SJ, Given CA 2nd (2006) Case 99: Canavan disease. Radiology 241(1):310–314. doi:10.1148/radiol.2411040165
Zaki OK, El Abd HS, Mohamed SA, Zayed H (2015) Novel mutation in an Egyptian patient with infantile Canavan disease. Metab Brain Dis. doi:10.1007/s11011–015-9772-z
Acknowledgment
Hatem Zayed is supported by the Qatar University grant QUUG-CAS-DHS-14/15-3.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Conflict of interest statement
All author declare that they have no conflict of interest
Rights and permissions
About this article
Cite this article
Zaki, O.K., Krishnamoorthy, N., El Abd, H.S. et al. Two patients with Canavan disease and structural modeling of a novel mutation. Metab Brain Dis 32, 171–177 (2017). https://doi.org/10.1007/s11011-016-9896-9
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11011-016-9896-9